✦ LIBER ✦

Vaccination strategies for patients with inflammatory bowel disease on immunomodulators and biologics

✍ Scribed by Gil Y. Melmed

Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 86 KB
Volume: 15
Category: Article
ISSN: 1078-0998
DOI: 10.1002/ibd.20943

No coin nor oath required. For personal study only.

✦ Synopsis

The treatment of Crohn's disease and ulcerative colitis frequently includes potent immunomodulator and biologic therapy to reduce intestinal inflammation, heal fistulae, limit complications, and improve quality of life. These medications may increase susceptibility to and severity of infections, many of which are preventable by preemptive immunizations. Conversely, live-virus vaccines are generally contraindicated in patients receiving immunosuppressive regimens due to risks of vaccineassociated infection. While most patients on immunosuppressive therapies develop immune responses after vaccinations, these may be impaired relative to their nonimmunosuppressed counterparts. This review discusses the rationale for currently recommended vaccinations, as well as issues pertaining to vaccine safety and immunogenicity in immunosuppressed patients with inflammatory bowel disease and their household contacts.

📜 SIMILAR VOLUMES

Stopping immunomodulators and biologics

Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission

✍ Kofi Clarke; Miguel Regueiro 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 86 KB

The emergence of biologic response modifiers and earlier use of immunomodulators for inflammatory bowel disease (IBD) patients have improved outcomes. Durable remissions have been achieved in many IBD patients on these treatments, but the duration of treatment and identifying which patients may stop

Use of biologics in inflammatory bowel d

Use of biologics in inflammatory bowel disease patients with cirrhosis

✍ Tanvi Dhere 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 40 KB 👁 2 views

Safety of immunomodulators and biologics

Safety of immunomodulators and biologics for the treatment of inflammatory bowel disease during pregnancy and breast-feeding

✍ Javier P. Gisbert 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 154 KB 👁 2 views

The aim of this article is to critically review available data regarding the safety of immunomodulators and biological therapies during pregnancy and breast-feeding in women with inflammatory bowel disease. Methotrexate and thalidomide can cause congenital anomalies and are contraindicated during pr

Systematic review of postoperative compl

Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators

✍ V. Subramanian; R. C. G. Pollok; J.-Y. Kang; D. Kumar 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 109 KB 👁 2 views

## Abstract ## Background This systematic review examined the use of immunomodulators and the risk of postoperative complications after abdominal surgery in patients with inflammatory bowel disease. ## Methods Electronic databases (PubMed, Embase, Ingenta, Zetoc and Ovid) were searched and the r

Response Friedman and Sparrow re: Stoppi

Response Friedman and Sparrow re: Stopping immunomodulators and biologics in inflammatory bowel disease patients in remission. Inflamm Bowel Dis 2011 [Epub ahead of print].

✍ Kofi Clarke; Miguel Regueiro 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 37 KB 👁 1 views

Disparities in the use of immunomodulato

Disparities in the use of immunomodulators and biologics for the treatment of inflammatory bowel disease: A retrospective cohort study

✍ Mark H. Flasar; Tamara Johnson; Mary-Claire Roghmann; Raymond K. Cross 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 104 KB 👁 2 views

## Background: Treatment disparities between african americans (aa) and caucasians exist in multiple diseases. there are limited studies in inflammatory bowel disease (ibd). our objectives were to assess differences in ibd therapies between aa and caucasians, controlling for disease severity. ## M